Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACT Biotech Inc.

This article was originally published in Start Up

Executive Summary

Oncology-focused ACT Biotech acquired its oral kinase programs from Bayer when it merged with Schering. The start-up's lead compound is telatinib, a potent and selective orally available inhibitor of three receptor tyrosine kinases. According to ACT, it is the most selective kinase inhibitor yet developed. That selectivity imparts an excellent safety profile, which makes it well tolerated at high, continuous doses. The candidate also has no overlapping side effects with other chemotherapy drugs.

You may also be interested in...



Start-Up Previews (04/2011)

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.

Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.

X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel